Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study

BACKGROUND: Antiretroviral options for neonates (younger than 28 days) should be expanded. We evaluated the pharmacokinetics, safety, and acceptability of the "4-in-1" fixed-dose pediatric granule formulation of abacavir/lamivudine/lopinavir/ritonavir (30/15/40/10 mg) in neonates. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekker, Adrie, Rabie, Helena, Salvadori, Nicolas, du Toit, Samantha, Than-in-at, Kanchana, Groenewald, Marisa, Andrieux-Meyer, Isabelle, Kumar, Mukesh, Cressey, Ratchada, Nielsen, James, Capparelli, Edmund, Lallemant, Marc, Cotton, Mark F., Cressey, Tim R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826609/
https://www.ncbi.nlm.nih.gov/pubmed/34855626
http://dx.doi.org/10.1097/QAI.0000000000002871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826609/
https://www.ncbi.nlm.nih.gov/pubmed/34855626
http://dx.doi.org/10.1097/QAI.0000000000002871

Ejemplares similares